NCT01272323

Cat-PAD Follow on Study

An Optional 1 Year Follow up Study to Evaluate the Continued Efficacy of Cat-PAD in Cat Allergic Subjects Following Challenge to Cat Allergen in an Environmental Exposure Chamber

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 170 (estimated)
• Sponsor: Circassia Limited · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma. The purpose of this optional observational follow-on study is to further evaluate rhinoconjunctivitis symptoms on exposure to cat dander in the EEC among subjects who completed all dosing visits in study CP005 approximately one year after the start of treatment.

Detailed description

Subjects who completed all dosing visits and the post treatment challenge (PTC) in study CP005 will be invited to attend the Screening Visit for CP005A. Subjects will attend for 4 visits to the EEC on successive days. Following the last EEC visit a follow-up visit will be performed 3-10 days later.

Conditions

• Cat Allergy
• Rhinoconjunctivitis

Interventions

Type	Name	Description
BIOLOGICAL	Placebo	No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
BIOLOGICAL	Cat-PAD Dose 1	No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
BIOLOGICAL	Cat-PAD Dose 2	No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.

Timeline

• Start date: 2011-02-01
• Primary completion: 2011-04-01
• Completion: 2011-04-01
• First posted: 2011-01-07
• Last updated: 2011-05-20

Locations

1 site across 1 country: Canada